Sign in to view content

Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2022

Related

Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Therapeutic Horizons for Dry AMD
Robert L. Avery, MD
Updates from the Field
2019
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018

Category: Age-Related Macular Degeneration

See more